The direct answer is that the supplied brief does not prove a regulatory breach, but it does identify a disclosure issue investors and market watchers should examine carefully. Dr. Plant says its model is distribution, not franchising, because it does not collect franchise fees, management fees, or brand-use fees from distributors. At the same time, the brief says its website presents a franchise-support page for prospective merchants. The key unresolved question is whether those two descriptions refer to the same business reality in materially different ways.
| Primary source | Wallstreetcn |
|---|---|
| Reported at | 2026-07-14T11:06:00.000Z |
| Topic | 公司 |
| Evidence limit | Reported facts are separated from interpretation; current prices and platform terms require independent verification. |
Evaluate BINANCE for your use case
Check regional eligibility, current fees and product availability on the official destination.
Review BINANCEWhat Happened
According to the supplied July 14, 2026 brief, Beijing Dr. Plant Cosmetics Co., Ltd. updated its IPO prospectus and continued pursuing a Shanghai main board listing. The report focuses on a tension between how the company describes its offline sales model to regulators and how it presents support for prospective store partners.
In the IPO inquiry response described in the brief, Dr. Plant denies that its sales model is a franchise model. Its stated reasoning is that it does not charge distributors franchise fees, management fees, brand-use fees, or similar fees, and that its profit mainly comes from selling products to distributors.
The same brief says Dr. Plant's website has a merchant-facing page translated here as franchise support. That page is described as offering store location assessment, store image design, cashier software support, pre-opening training, monthly training, opening preparation, opening activity support, and later-stage operational coaching.
Why It Matters
For readers, the issue is whether the same store network is being framed differently depending on the audience. If the IPO materials emphasize distribution while merchant-facing materials use franchise-support language, investors may want clearer disclosure about operational control, brand use, fee structure, risk-bearing, and profit sources.
The supplied brief says regulators asked Dr. Plant to explain whether its sales model should be regarded as franchising by considering factors such as trademark and brand use, control over store operations, whether stores pay franchise fees, sources of profit, and risk allocation. The brief does not provide a final regulatory conclusion.
That means the careful reading is evidence-limited: the story raises a consistency question, but it does not establish that Dr. Plant has misled regulators or that its IPO will fail.
Business Context
The disclosure question matters because Dr. Plant's offline channel remains central to its revenue base. The supplied brief says the company had 4,268 offline chain stores at the end of 2025, with 480 directly operated terminal stores and 3,788 authorized distributor stores.
The brief says the distribution model generated 1.402 billion yuan of revenue in 2025, accounting for more than 60% of revenue. That makes the classification and explanation of this network important for anyone trying to understand the IPO story.
Growth also appears limited in the supplied numbers. In 2025, Dr. Plant reported revenue of 2.167 billion yuan, up only 0.53%, while net profit attributable to shareholders was 218 million yuan, down by more than 10%.
Channel Shift
The supplied brief describes a two-track strategy: reduce less efficient offline stores while adding more online growth. The company strengthened single-store cost-benefit assessment and closed some underperforming distributor stores after discussions with relevant distributors.
By the end of 2025, authorized distributor stores totaled 3,788, down by 336 from 2023. The brief says the company linked the decline to maintaining brand image, improving potential distributor willingness to open stores, and closing lower-performing stores.
Dr. Plant is also described as expanding instant retail through Meituan and JD.com, while using its Xiaozhi Mall to connect offline consumers and member relationships to online repeat purchases. The brief says Xiaozhi Mall generated 183 million yuan in 2025, close to 10% of revenue.
Practical Checks
A practical reader should compare three things before drawing a conclusion: the wording in the IPO filing, the full merchant-facing recruitment page, and the economic substance of the store relationship. The important question is not whether one page uses a familiar commercial label, but whether rights, fees, controls, and risks are explained consistently.
Readers should also separate operating performance from disclosure quality. Slow revenue growth, lower attributable profit, fewer distributor stores, and higher net margin are different signals. They can coexist, and none of them alone answers whether the offline model is distribution or franchising.
Because the supplied brief is the only factual source used here, this article does not independently verify the prospectus, the company website, regulator communications, or later company explanations.
Risk and Conversion Context
This article is for market information only and is not financial advice. It does not recommend buying, selling, subscribing to, or avoiding any security, token, or financial product. IPO outcomes, market reactions, and regulatory reviews cannot be inferred from this brief alone.
For readers who follow company news alongside crypto-market news, the practical next step is to keep a watchlist of disclosure updates, prospectus revisions, and follow-up explanations rather than trade on a single narrative. If you choose to use the supplied Binance signup link, review eligibility, fees, platform terms, and risk disclosures first: BINANCE official destination. The supplied referral code is 7nfg8123.
Evaluate BINANCE for your use case
Check regional eligibility, current fees and product availability on the official destination.
Review BINANCEAffiliate link · Availability varies by region · No guaranteed outcomeQuestions readers ask
What is the main issue in Dr. Plant's IPO story?
The main issue is whether Dr. Plant's offline authorized store network is being described consistently. The supplied brief says the company tells regulators the model is distribution, not franchising, while merchant-facing website material uses franchise-support language.
Does the supplied brief prove Dr. Plant violated disclosure rules?
No. The supplied brief raises a disclosure-consistency question, but it does not prove a regulatory breach, misstatement, or IPO outcome.
Why does the distributor versus franchise distinction matter?
It matters because the classification can affect how readers understand store control, brand use, fee structure, profit source, risk allocation, and the reliability of IPO disclosure around a revenue-critical channel.
How important are offline stores to Dr. Plant's business?
According to the supplied brief, Dr. Plant had 4,268 offline stores at the end of 2025, including 3,788 authorized distributor stores, and its distribution model contributed 1.402 billion yuan of revenue in 2025.
What financial pressure does the brief describe?
The brief says Dr. Plant's 2025 revenue was 2.167 billion yuan, up 0.53%, while net profit attributable to shareholders was 218 million yuan, down by more than 10%.
What should readers watch next?
Readers should watch for follow-up explanations from Dr. Plant, any revised IPO disclosure, further regulatory questions, and clearer detail on whether merchant-facing franchise-support language matches the economic substance of the company's distributor-store relationships.